# Real-world Health Outcomes in Canadian Patients Using Semaglutide

> **NCT04175665** · — · COMPLETED · sponsor: **LMC Diabetes & Endocrinology Ltd.** · enrollment: 1133 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT04175665
- **Lead sponsor:** LMC Diabetes & Endocrinology Ltd.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-06
- **Primary completion:** 2020-02-09
- **Final completion:** 2020-02-09
- **Target enrollment:** 1133 (ACTUAL)
- **Last updated:** 2020-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04175665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04175665, "Real-world Health Outcomes in Canadian Patients Using Semaglutide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04175665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*